TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors.
Zhiwei CuiHaoyu SunZhishuang GaoChao LiTingting XiaoYibo BianZonghang LiuTianhao GuJianan ZhangTengyun LiQianzheng ZhouZhongyuan HeBowen LiFengyuan LiZekuan XuHao XuPublished in: British journal of cancer (2024)
These findings demonstrate that the TRIM21 and USP15 control ACSL4 stability to maintain the IM sensitive/resistant status of GIST.
Keyphrases